Long-acting cabotegravir plus rilpivirine for treatment in adults with HIV-1 infection: 96-week results of the randomised, open-label, phase 3 FLAIR study
Chloe Orkin, Shinichi Oka, Patrick Philibert, Cynthia Brinson, Ayesha Bassa, Д. А. Гусев, Olaf Degen, Juan González‐García, Enrique Bernal, Darrell H. S. Tan, Ronald D’Amico, David Dorey, Sandy Griffith, Shanker Thiagarajah, Marty St. Clair, Rodica Van Solingen‐Ristea, Herta Crauwels, Susan L. Ford, Parul Patel, Vasiliki Chounta, Simon Vanveggel, Amy Cutrell, Veerle Van Eygen, Kati Vandermeulen, David A. Margolis, Kimberly Y. Smith, William Spreen
Topics & Concepts
RilpivirineMedicineDolutegravirAbacavirEmtricitabineRegimenLamivudineInternal medicineViral loadHuman immunodeficiency virus (HIV)Antiretroviral therapyVirologyHepatitis B virusVirusHIV/AIDS Research and InterventionsHIV/AIDS drug development and treatmentHIV-related health complications and treatments